This is a general collection of COVID-19 data deposited in the Harvard Dataverse repository. The list in this collection is maintained by the Harvard Dataverse data curation team (IQSS and Harvard Library). Researchers who deposit their related data into Harvard Dataverse will have their data linked to this collection, to increase discoverability of their data. Please use the contact link if you have any questions about this collection.
Featured Dataverses

In order to use this feature you must have at least one published or linked dataverse.

Publish Dataverse

Are you sure you want to publish your dataverse? Once you do so it must remain published.

Publish Dataverse

This dataverse cannot be published because the dataverse it is in has not been published.

Delete Dataverse

Are you sure you want to delete your dataverse? You cannot undelete this dataverse.

Advanced Search

81 to 90 of 58,664 Results
pactr.samrc.ac.za_TrialDisplay.aspx_TrialID=25747.pdf
May 2, 2025 - SPIRIT 2013 Checklist: Hydroxyurea - Pragmatic Reduction In Mortality and Economic burden (H-PRIME): A 2x2x2 factorial randomised open-label trial investigating practical approaches to the treatment of sickle cell disease at four sites in Eastern Uganda: ISRCTN 15724013
Adobe PDF - 287.7 KB - MD5: 3c30329ab7845566fcd1f5a766b1e880
PACTR Registration File
Extended Data for: Hydroxyurea - Pragmatic Reduction In Mortality and Economic burden (H-PRIME): A 2x2x2 factorial randomised open-label trial investigating practical approaches to the treatment of sickle cell disease at four sites in Eastern Uganda: ISRCTN 15724013
May 2, 2025 - Human Genetic Factors (HGF) Group
Williams, Tom, 2025, "Extended Data for: Hydroxyurea - Pragmatic Reduction In Mortality and Economic burden (H-PRIME): A 2x2x2 factorial randomised open-label trial investigating practical approaches to the treatment of sickle cell disease at four sites in Eastern Uganda: ISRCTN 15724013", https://doi.org/10.7910/DVN/DKR3LX, Harvard Dataverse, V1
The package contains extended data for the protocol titled "Hydroxyurea - Pragmatic Reduction In Mortality and Economic burden (H-PRIME): A 2x2x2 factorial randomised open-label trial investigating practical approaches to the treatment of sickle cell disease at four sites in Eastern Uganda: ISRCTN 15724013"
101_H-PRIME patient information sheet ΓÇô parents and carers v2.06.docx
May 2, 2025 - Extended Data for: Hydroxyurea - Pragmatic Reduction In Mortality and Economic burden (H-PRIME): A 2x2x2 factorial randomised open-label trial investigating practical approaches to the treatment of sickle cell disease at four sites in Eastern Uganda: ISRCTN 15724013
MS Word - 165.6 KB - MD5: a3e388b1ebfece28d4b38e47d9ae6018
102_H-PRIME TRIAL patient information sheet older children v2.06.docx
May 2, 2025 - Extended Data for: Hydroxyurea - Pragmatic Reduction In Mortality and Economic burden (H-PRIME): A 2x2x2 factorial randomised open-label trial investigating practical approaches to the treatment of sickle cell disease at four sites in Eastern Uganda: ISRCTN 15724013
MS Word - 50.5 KB - MD5: 205b0f38f7a4b77982d3aef0f5c12583
103_H-PRIME consent form for screening v2.06.docx
May 2, 2025 - Extended Data for: Hydroxyurea - Pragmatic Reduction In Mortality and Economic burden (H-PRIME): A 2x2x2 factorial randomised open-label trial investigating practical approaches to the treatment of sickle cell disease at four sites in Eastern Uganda: ISRCTN 15724013
MS Word - 164.6 KB - MD5: 73030510d7d650507b9e1866f1813ef7
104_H-PRIME TRIAL consent form - parents and carers v2.06.docx
May 2, 2025 - Extended Data for: Hydroxyurea - Pragmatic Reduction In Mortality and Economic burden (H-PRIME): A 2x2x2 factorial randomised open-label trial investigating practical approaches to the treatment of sickle cell disease at four sites in Eastern Uganda: ISRCTN 15724013
MS Word - 163.7 KB - MD5: 41d9c14e32a845e764955f5334667d1e
105_H-PRIME TRIAL assent form v2.06.docx
May 2, 2025 - Extended Data for: Hydroxyurea - Pragmatic Reduction In Mortality and Economic burden (H-PRIME): A 2x2x2 factorial randomised open-label trial investigating practical approaches to the treatment of sickle cell disease at four sites in Eastern Uganda: ISRCTN 15724013
MS Word - 164.4 KB - MD5: 1e1a43dded6ac06e350a7d7460f4dc99
106_H-PRIME TRIAL patient information sheet specimen storage v2.06.docx
May 2, 2025 - Extended Data for: Hydroxyurea - Pragmatic Reduction In Mortality and Economic burden (H-PRIME): A 2x2x2 factorial randomised open-label trial investigating practical approaches to the treatment of sickle cell disease at four sites in Eastern Uganda: ISRCTN 15724013
MS Word - 165.2 KB - MD5: 2b4e2b9faef5b6b30101be6a9a0d646a
107_H-PRIME TRIAL consent form specimen storeage v2.06.docx
May 2, 2025 - Extended Data for: Hydroxyurea - Pragmatic Reduction In Mortality and Economic burden (H-PRIME): A 2x2x2 factorial randomised open-label trial investigating practical approaches to the treatment of sickle cell disease at four sites in Eastern Uganda: ISRCTN 15724013
MS Word - 163.0 KB - MD5: a656d060082fdbc8c6b35fd47fd71de4
10_HPRIME_Form10_local FBC_v3.0_20241218_clean.docx
May 2, 2025 - Extended Data for: Hydroxyurea - Pragmatic Reduction In Mortality and Economic burden (H-PRIME): A 2x2x2 factorial randomised open-label trial investigating practical approaches to the treatment of sickle cell disease at four sites in Eastern Uganda: ISRCTN 15724013
MS Word - 29.6 KB - MD5: 96ce37374a40753f65abbebd9e8adec2
Add Data

Sign up or log in to create a dataverse or add a dataset.

Sign Up Log In
Share Dataverse

Share this dataverse on your favorite social media networks.

Link Dataverse
Reset Modifications

Are you sure you want to reset the selected metadata fields? If you do this, any customizations (hidden, required, optional) you have done will no longer appear.